Literature DB >> 34889382

Treatment dilemmas: strategies for priapism, chronic leg ulcer disease, and pulmonary hypertension in sickle cell disease.

Roberta C G Azbell1,2, Payal Chandarana Desai1,3.   

Abstract

Sickle cell disease is a disorder characterized by chronic hemolytic anemia and multiorgan disease complications. Although vaso-occlusive episodes, acute chest syndrome, and neurovascular disease frequently result in complication and have well-documented guidelines for management, the management of chronic hemolytic and vascular-related complications, such as priapism, leg ulcers, and pulmonary hypertension, is not as well recognized despite their increasing reported prevalence and association with morbidity and mortality. This chapter therefore reviews the current updates on diagnosis and management of priapism, leg ulcers, and pulmonary hypertension.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 34889382      PMCID: PMC8791181          DOI: 10.1182/hematology.2021000275

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  40 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

2.  Laboratory and echocardiography markers in sickle cell patients with leg ulcers.

Authors:  Caterina P Minniti; James G Taylor; Mariana Hildesheim; Patricia O'Neal; Jonathan Wilson; Oswaldo Castro; Victor R Gordeuk; Gregory J Kato
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

3.  Hydroxyurea in the treatment of sickle cell associated priapism.

Authors:  A H Al Jam'a; I A Al Dabbous
Journal:  J Urol       Date:  1998-05       Impact factor: 7.450

Review 4.  Sickle cell disease as a vascular disorder.

Authors:  Solomon F Ofori-Acquah
Journal:  Expert Rev Hematol       Date:  2020-05-03       Impact factor: 2.929

5.  A hemodynamic study of pulmonary hypertension in sickle cell disease.

Authors:  Florence Parent; Dora Bachir; Jocelyn Inamo; François Lionnet; Françoise Driss; Gylna Loko; Anoosha Habibi; Soumiya Bennani; Laurent Savale; Serge Adnot; Bernard Maitre; Azzedine Yaïci; Leila Hajji; Dermot S O'Callaghan; Pierre Clerson; Robert Girot; Frederic Galacteros; Gerald Simonneau
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

6.  Sickle cell disease and leg ulcers.

Authors:  Barry Ladizinski; Andrea Bazakas; Nisha Mistry; Afsaneh Alavi; R Gary Sibbald; Richard Salcido
Journal:  Adv Skin Wound Care       Date:  2012-09       Impact factor: 2.347

7.  Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease.

Authors:  Samir K Ballas; David Lyon
Journal:  J Clin Apher       Date:  2015-03-25       Impact factor: 2.821

8.  N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.

Authors:  Roberto F Machado; Anastasia Anthi; Martin H Steinberg; Duane Bonds; Vandana Sachdev; Gregory J Kato; Angelo M Taveira-DaSilva; Samir K Ballas; William Blackwelder; Xiuli Xu; Lori Hunter; Bruce Barton; Myron Waclawiw; Oswaldo Castro; Mark T Gladwin
Journal:  JAMA       Date:  2006-07-19       Impact factor: 56.272

Review 9.  Interventions for treating leg ulcers in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Jennifer M Knight-Madden; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2021-01-09

Review 10.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.